SOUTH SAN FRANCISCO, Calif.,
April 26, 2016 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its first quarter 2016 financial
results after market close on Tuesday, May
3, 2016. Rigel senior management will follow the
announcement with a live conference call and webcast at
5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial
results.
Participants can access the live conference call by dialing
855-892-1489 (domestic) or 720-634-2939 (international) and using
the Conference ID number 97470871. The conference call will
also be webcast live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and
available for replay for 30 days after the call via the Rigel
website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a clinical-stage biotechnology company dedicated to the
discovery and development of novel, targeted drugs in the
therapeutic areas of immunology, oncology and immuno-oncology.
Rigel's pioneering research focuses on signaling pathways that are
critical to disease mechanisms. The company's current clinical
programs include fostamatinib, an oral spleen tyrosine kinase (SYK)
inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2
clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase
2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has
two oncology product candidates in Phase 1 development with
partners BerGenBio AS and Daiichi Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
mail: susan@rivily.com
Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2016-financial-results-300257154.html
SOURCE Rigel Pharmaceuticals, Inc.